A risk-benefit assessment of growth hormone use in children

Drug Safety

Volumn 17, Issue 5, 1997, Pages 303-316

  Blethen, Sandra L ^a   MacGillivray, Margaret H ^b  

^a GENENTECH INC   (United States)

^b CHILDREN S HOSPITAL OF BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GROWTH HORMONE;

BONE DENSITY; BONE MINERAL; CARPAL TUNNEL SYNDROME; EDEMA; GROWTH HORMONE DEFICIENCY; HUMAN; INTRACRANIAL HYPERTENSION; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SHORT STATURE; SOCIAL PSYCHOLOGY; TURNER SYNDROME;

EID: 0030690256     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199717050-00003     Document Type: Review

References (128)

1. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1458; 18: 901-3
2. Preecc M. Human pituitary growth hormone and Creutzfeldt-Jakob disease. Horm Res 1993; 39: 95-8
3. Raiti S. Statistical aspects of rhGH therapy for hypopituitarism. Pediat Adolesc Endocrinol 1987; 16: 1-12
4. Tanner JM, Whitehouse RH, Hughes PC, et al. Effect of human growth hormone treatment for 1 to 7 years on growth of I(X) children with growth hormone deficiency, low birthweight, inherited smallness. Turner syndrome, and other complaints. Arch Dis Child 1971; 46: 745-82
5. Blethen SL, Complon P, Lippe BM, et al. Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency. J Clin Endocrinol Metah 1993; 76: 573-6
6. Ranke MB, Builbaud G. Growth response in prepubertal children with idiopathic growth hormone deficiency during the first two years of treatment with human growth hormone: analysis of the Kabi Pharmacia International Growth Study. Acta Paediatr Scand 1991; 379 Suppl.: 109-15
7. MacGillivray MH, Baptista J, Johanson A, Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormonedeficient children. Genentech Study Group. J Clin Endocrinol Metab 1996; 81: 1806-9
8. Rosenfeld, RG, Albertsson-Wikland K, Cassorla F, et al. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 1995; 80: 1532-40
9. Tillmann V, Buckler JMH, Kibirige MS, et al. Biochemical tests in the diagnosis of childhood growth hormone deficiency. J Clin Endocrinol Metab 1997; 82: 531-5
10. Hasegawa Y, Hasegawa T, Aso T, et al. Usefulness and limitations of measurement of insulin-like growth factor binding prolcins-3 (IGFBP-3) for diagnosis of growth hormone deficiency. Endocrinol Jpn 1992; 39: 585-91
11. Blum WF, Albertsson-Wikland K, Rosberg S, et al. Serum levels of IGF-I and IGFBP-3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993; 76: 1612-6
12. Spiliotis BE, August GP, Hung W, et al. Growth hormone neurosecretory dysfunction: a treatable cause of short stature. JAMA 1984; 251: 2223-30
13. Rose DR, Rose H, Uriarte M, et al. The advantage of measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis of growth hormone deficiency. N Engl J Med 1988; 319: 201-7
14. Albertsson-Wikland K. Growth hormone treatment in short children: short-term and long-term effects on growth. Acta Paediatr Scand 1988; 343 Suppl.: 77-84
15. Lesagc C, Walker M, Landier F, et al. Near normalization of adolescent height with growth hormone therapy in very short children without growth hormone deficiency. J Pediatr 1991; 119: 29-34
16. Moore WV, Moore KC, Gifford R, et al. Long-term treatment with growth hormone of children with short stature and normal growth hormone secretion. J Pediatr 1992; 120: 702-8
17. Hopwood NJ, Hintz RL, Germer JM, et al. Growth response of children with non-growth hormone deficiency and marked shim stature during three years of growth hormone therapy. J Pediatr 1993; 123: 215-22
18. Hintz RL. Growth hormone treatment of idiopathic short stature. Horm Res 1996; 46: 208-14
19. Sridhar GR. Hypoglycemia due to sedation following clonidine test for growth hormone reserve. Clin Pediatr 1993; 32: 688-9
20. Cowell C, Dietsch S, Greenacre P. Growth hormone therapy for three years in growth hormone deficient and non growth hormone deficient children: the OZGROW experience. J Paediatr Child Health 1995; 8: 243-54
21. Werther GA. Growth hormone measurements versus auxology in treatment decisions: the Australian experience. J Pediatr 1996; 128 Suppl.: S47-51
22. Silink M. Alternative methods of diagnosis of growth hormone deficiency. J Pediatr Endocrinol 1992; 5: 43-52
23. Takano K, Shizume K, Hibi I. Turner's syndrome: treatment of 203 patients with recombinant human growth hormone for one year. Acta Endocrinol 1988; 120: 559-68
24. Lin TH, Kirkland JS, Kirkland RT. Growth hormone assessment and short term treatment with growth hormone in Turner syndrome. J Pediatr 1988; 112: 919-21
25. Rosenfeld RG, Franc J, Attie KM, et al. Six year results of a randomized prospective trial of human growth hormone and oxandrolone in Turner syndrome. J Pediatr 1992; 21: 49-55
26. Haeusler G, Frisch H. Growth hormone treatment in Turner's syndrome: short and long term effects on metabolic parameters. Clin Endocrinol 1992; 36: 247-54
27. Tonshoff B, Mehls O, Heinrich U, et al. Growth-stimulating effect of recombinant growth hormone in children with endslage renal disease. J Pediatr 1990; 116: 561-7
28. 2X. Fine RN, Kohaut E, Brown R, et al. Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a placebo-controlled study. J Pediatr 1994; 124: 374-82
29. Fine KN, Brown DF, Kuntze J, et al. Growth after discontinuation of recombinant human growth hormone therapy in children with chronic renal insufficiency: The Genentech Cooperative Study Group. J Pediatr 1996; 12: 883-91
30. Fine RN, Stablein DM, Tejani A. Do children exhibit catch-up growth post-transplant: North American Pediatric Renal Transplant Cooperative Study special study. Pediatr Nephrol 1995; 9 Suppl.: S66-68
31. Fine RN, Yadin O, Moulton L, et al. Five years experience with recombinant human growth hormone treatment of children with chronic renal failure. J Pediatr Endocrinol 1994; 7: 1-12
32. Mehls O, Haffner D, Wuhl E, et al. Growth hormone as a new treatment modality for short children with chronic renal failure: the German study group for growth hormone treatment in chronic renal failure. Horm Res 1996; 46: 230-5
33. Burns EC, Tanner JM, Preece MA, et al. Growth hormone treatment in children with craniopharyngioma: final growth status. Clin Endocrinol 1981; 14: 587-95
34. Burns EC, Tanner JM, Preece MA, et al. Height and pubertal development in 55 children with idiopathic growth hormone deficiency treated for between 2 and 15 years with human growth hormone. Eur J Pediatr 1981; 137: 155-63
35. Joss E, Zuppinger K, Schwarz HP, et al. Final height of patients with pituitary growth failure und changes in growth variables after long term hormonal therapy. Pediatr Res 1983; 17: 676-9
36. Bourguignon J-P, Vanderweghe M, Vanderschueren-Lodeweyckx M, et al. Pubertal growth and final height in hypopituitary males: a minor role of hone age at onset of puberty. J Clin Endoerinol Metab 1986; 63: 376-82
37. Hibi I, Tanaka T, Final height of patients with idiopathic growth hormone deficiency after long-term treatment. Acta Endocrinol (Copenh) 1989; 120: 409-15
38. Libber SM, Plotnick LP, Johanson AJ, et al. Long-term follow-up of hypopituitary patients treated with human growth hormone. Medicine 1990; 69: 46-55
39. Rimoin DL, Mcrimee TJ, Tabinowitz D, et al. Genetic aspects of clinical endocrinology. Rec Prog Horm Res 1968; 24: 365-437
40. Ranke MB. A note on adults with growth hormone deficiency. Acta Paediatr Scand 1987; 331 Suppl.: 80-2
41. Van der Werff ten Bosch JJ, Bot A. Growth of males with idiopathic hypopituitarism without growth hormone treatment. Clin Endocrinol 1990; 32: 707-17
42. Wit JM, Kamp GA, Rikken B. Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature. Pediatr Res 1996; 39: 295-302
43. Tanner JM, Whitehouse RH, Marshall WA, et al. Assessment of skeletal maturity und prediction of adult height (TW2 method). London: Academic Press. 1975
44. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with Greulich-Pyle hand standards. J Pediatr 1952; 40: 432-41
45. Zachmann M, Sohradillo B, Frank M, et al. Bayley-Pinneau, Roche-Wainer-Thissen and Tanner height predictions in normal children and in patients with various pathologic conditions. J Pediatr 1978; 93: 749-55
46. Blethen SL, Baptista J, Kuntze J, et al. Adult heighl in growth hormone (GH)-deficient children treated with biosynthetic GH. J Clin Endocrinol Metab 1997; 82: 418-20
47. Price DA, Ranke MB. Final height following growth hormone treatment. In: Progress in growth hormone therapy - 5 years of KIGS, Ranke MB, Gunnarsson K, editors. Mannheim: J&J Verlag. 1994: 129-44
48. DeLuca K, Haghnie M, Arrigo T, et al. Final height outcome of growth hormone-deficient patients treated since less than five years of age. Aeta Paediatr 1996; 85: 1167-71
49. Darendeliler F, Hindmarsh PC, Preece MA, et al. Growth hormone inereases rate of pubertal maturation. Acta Endocrinol 1990; 122: 414-6
50. Hochberg Z, Leiberman K, Landau H, et al. Age as a determinant of the impact of growt hormone therapy on predicted adult height. Clin Endocrinol 1994; 41: 331-5
51. Buckler JMH. How to make the most of bone ages. Arch Dis Child 1983; 58: 761-3
52. Loder RT, Estle DT, Morrison K, et al. Applicability of the Greulich and Pyle skeletal age standards to black and while children of today. Am J Dis Child 1993; 147: 1329-33
53. Blethen SL, Gaines S, Weldon VV. Comparison of predicted and adult heights in short boys: effect of androgen therapy. Pediatr Res 1984: 467-9
54. LaFranchi S, Hanna CE, Mandel SH. Constitutional delay of growth: expected versus final adult height. Pediatrics 1991; 87: 82-7
55. Ranke MB, Grauer ML, Kistner K, et al. Spontaneous adult height in idiopathic short stature. Horm Res 1995; 44: 152-7
56. Pasquino AM, Passeri F, Municchi G, et al. Final height in Turner syndrome patients treated with grrwth hormone. Horm Res 1996; 46: 269-72
57. Rosenfeld RG, Attie KM, Frane JW, et al. Growth hormone therapy of Turner syndrome: effect on final height. J Pediatr. In press
58. Ranke MB, Grauer ML, Adult height in Turner syndrome: results of a multinational survey 1993. Horm Res 1944; 42: 90-4
59. Hunt SM. Developing a measure of quality of life for adults with growlh hormone deficiency. Drug Inf J 1994; 28: 3-11
60. Dean H, McTaggart T, Fish D, et al. The educational, vocational and marital status of growth hormone deficient adults treated with growth hormone during childhood. Am J Dis Child 1985; 139: 1105-10
61. McGauley G, Cuneo K, Salomon F, et al. Growth hormone deficiency and quality of life. Horm Res 1996; 45: 34-7
62. Rikken B, van Busschbach J, le Cessie S, et al. Impaired social status of growth hormone deficient adults as co npared to controls with short or normal stature. Clin Endocrinol 1995; 43: 205-11
63. Stabler B, Turner JR, Girdler SS, et al. Reactivity to stress and psychological adjustment in adults with pituitary insufficiency. Clin Endocrinol 1992; 36: 467-73
64. Stabler B, Clopper RR, Siegal PT, et al. Academic achievement and psychological adjustment in short children. J Dev Behav Pediatr 1994; 15: 1-6
65. Clopper RR, MaeGillivray MH, Mazur T, et al. Post-treatment follow-up of growlh hormone deficient patients: psychosocial status. In: Stabler B, Underwood LE, editors. Slow grows the child: psychosocial aspects of growth delay. Hillsdale (NJ): Lawrence Erlbaum Associates. 1986; 83-96
66. Mitchell CM, Libber S, Johanson AJ, et al. Psychosocial impact of long-term growth hormone therapy. In: Stabler B, Underwood I.E, editors. Slow grows the child: psychosocial aspects of growth delay. Hillsdale, NJ: Lawrence Erlbaum Associates. 1986: 97-109
67. DeBoer H, Blik GJ, van der Veen E. Clinical aspects of growth hormone deficiency in adults. Endocrinol Rev 1995; 16: 63-86
68. Ehrnborg C, Rosen T, Roijin LV. et al. Cost of illness study of adult hypopituitary patients. Abstracts 79th Annual Meeting of The Endocrine Society: 1997 Jun 11-14: Minneapolis (MN): 3-100
69. Underwood LE. The social cost of being short: societal perceptions and biases. Acta Paediatr Scand 1991; 377 Suppl.: 3-9
70. Frankel SA. Psychological complications of short stature in childhood. Some implications of the role of visual comparisons in normal and pathological development. Psychoanal Study Child 1996; 51: 455-74
71. Clopper R, Mazur T, Ellis MA, et al. Height and children's stereotypes. In: Stabler B, Underwood LE. editors. Growth, stature, and adaptation. An international symposium on the behaviorial, social, and cognitive aspects of growth delay: 1993 Oct 15-16: The University of North Carolina at Chapel Hill. Chapel Hill (NC), 1994: 7-18
72. Rosén T, Bengtsson B-Å. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-8
73. Bates AS, van't Hoff W, Jones PJ, et al. The effect of hypopituitarism on life expectancy. J Clin Endocrinal Metab 1996; 81: 1169-72
74. Markussis, Beshyah SA, Fisher C, et al. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992; 340: 1188-92
75. Wuster C, Slenczka E, Ziegler R. Increased prevalence of osteoporosis and arteriosclerosis in patients with conventionally substituted pituitary insufficiency: is there a need for additional growth hormone substitution? Klin Wochenschr 1991; 69: 769-93
76. Kaufman J-M, Taelman P, Venneulen A, et al. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 1992; 74: 118-23
77. Hyer SL, Rodin DA, Tobias JH, et al. Growth hormone deficiency during puberty reduces adult hone mineral density. Arch Dis Child 1992; 67: 1472-4
78. Bengtsson B-A, Edén S, Lönn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76: 309-17
79. Degerblad M, Elgindy N, Hall K, et al. Potent effect of recombinant growth hormone on bone mineral density and body composition in adults with panhypopituitarism. Acta Endocrinol (Copenh) 1992; 126: 387-93
80. Weaver JU, Monson JP, Noonan K, et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995; 80: 153-9
81. Burman P, Johansson AG, Siegbuhn A, et al. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997; 82: 550-5
82. Bjorntorp P. 'Portal' adipose tissue as a generator of risk factors for cardiovascular disease and diabetes [editorial]. Arterioselerosis 1990; 61: 1290-4
83. Neely EK, Marcus R, Rosenfeld RG, et al. Turner's syndrome adolescents receiving growth hormone arc not osleopcnic. J Clin Endocrinol Metab 1993; 76: 861-6
84. Lanes R, Guneczler P, Orta N, et al. Changes in hone mineral density, growth velocity and renal function of prepubertal uremic children during growth hormone treatment. Horm Res 1996; 46: 263-8
85. Saggese G, Baroncelli Gl, Bertelloni S, et al. Effects of long-term treatment un hone and mineral metabolism in children with growth hormone deficiency. J Pediatr 1993; 122: 37-45
86. Saggese G, Baroncelli GI, Bertelloni S, et al. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak hone mass. J Clin Endocrinol Metab 1996; 81: 3077-83
87. Mercola KE, Cline MJ, Golde DW. Growth honnone stimulation of normal and leukemic human T-lymphocyte proliferation in vitro. Blood 1981; 58: 337-40
88. Benfield MR, Vail A, Weigent DA. Recombinant human growth hormone augments responses in the mixed leukocyte culture. Transpl Proc 1994; 26: 84
89. Bozzola M, Valtorta A, Moretta A, et al. In vitro and in viva effect of growth hormone on cylotoxic activity. J Pediatr 1990; 117: 596-9
90. Gala RR. Prolactin and growth hormone in the regulation of the immune system. Proc Soc Exp Biol Med 1991; 198: 513-27
91. Araki K, Okada T, Fujieda M, et al. Immunological changes to growth hormone therapy in growth hormone deficiency. [abstract] Pediatr Res 1993; 33 Suppl.: S36
92. Bozzola M, Cistemino M, Larizza D, et al. Influence of growth hormone (GH) on natural killer (NK) activity in women with impaired endogenous growth hormone secretion |letter|. Metabolism 1989; 38: 193-4
93. Crist DM, Peake GT, Mackinnon TL, et al. Exogenous growth hormone treatment alters body composition and increases natural killer cell activity in women with impaired endogenous growth hormone secretion. Metabolism 1987; 36: 1115-7
94. Vara-Thorbeck R, Guerrero JA, Rosell J, et al. Exogenous growth hormone: effects on the catabolic response to surgically produced acute stress and on postoperative immune function. World J Surg 1993; 17: 530-8
95. Kaplan SL, Underwood LE, August G, et al. Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet 1986; 1: 697-700
96. Holcombe JH, Conforth PM, Wong AC, et al. Biosynthetic human growth hormone in the treatment of growth hormone deficiency. Acta Paediatr Scand 1990; 367 Suppl.: 44-8
97. Keizer-Schrama SMPF, Rikken B, et al. Dose-response study of biosynthetic human growth hormone (GH) in GH-deficient children: effects on auxological and biochemical parameters. J Clin Endocrinol Metab 1992; 74: 898-905
98. Auriche M, Loupi E. Does proof of causality ever exist in pharmacovigilance? Drug Saf 1993; 9: 230-5
99. Wilton P. Adverse events during growth hormone treatment: 5 years experience in the Kabi International Growth Study. In: Ranke MB, Gunnarsson R, editors. Progress in growth hormone therapy - 5 years of KIGS. Mannheim: PA J & J Verlag. 1994: 291
100. Cowell CT, Dietsch S. Adverse events during growth hormone therapy. J Pediatr Endocrinol Metab 1995; 8: 243-52
101. Blethen SL, Allen DB, Graves D, et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the National Cooperative Growth Study experience. J Clin Endocrinol Metab 1996; 81: 1704-10
102. Allen DB. Safely of human growth hormone therapy: current topics. J Pediatr 1946; 128 Suppl.: S8-13
103. Blethen SL, Rundle AC. Slipped capital femoral epiphysis in children treated with growth hormone: a summary of the National Cooperative Growth Study experience. Horm Res 1496; 46: 113-6
104. Tuffli GA, Johansnn A, Rundle AC, et al. Lack of increased risk lor extracranial nonlcukemic neoplasms in recipients of recombinant decoxyribonucleic acid growth hormone. J Clin Endocrinol Metab 1995; 80: 1416-22
105. Moshang T Jr., Rundle AC, Graves DA, et al. Brain tumor recurrence in children treated with growth hormone: the National Cooperative Growth Study experience. J Pediatr 1996; 128 Suppl.: S4-7
106. Malazowski S, Tanner AL, Wysowski DK, et al. Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J Pediatr 1995; 126: 996-9
107. Malazowski S, Stadel BV. Prepubertal gynecomastia during growth hormone therapy. J Pediatr 1995; 126: 659-61
108. Malazowski S, Hung W, Scott DC. Acute pancreatitis associated with growth hormone therapy for short stature. N Engl J Med 1995; 332: 401-2
109. Livieri C, Pedrotti L, Bonicelli I. et al. Scoliosis in Prader Willi syndrome: a supportive finding or a diagnostic criterion? [abstract]. Horm Res 1997; 48 Suppl.: 295
110. Fradkin JE, Mills JL, Schunberger LB, et al. Risk of leukemia after treatment with pituitary growth hormone. JAMA 1993; 270: 2829-32
111. Wantanabe S, Mizumo S, Oshima LH, et al. Leukemia and other malignancies among GH users. J Pediatr Endocrinol 1993; 6: 99-108
112. Butturini A, Bemasconi S, Izzi G, et al. Short stature, Fanconi's anemia, and risk of leukemia after growth hormone therapy. Lancet 1994:; 43: 1576
113. Allen DB, Rundle AC, Graves DA, et al. Risk for leukemia in children treated with human growth hormone: review and reanalysis. J Pediatr 1997; 131: 532-6
114. Kosary CL, Ries LAG, Miller BA, et al. Surveillance, epidemiology, and end result: program cancer statistics review. 1973-1992: tables and graphs. Bethesda (MD): National Cancer Institute, 1995. NIH Publication No. 96-2790.O16
115. Otten BJ, Rotteveel JJ, Cruysherg JRM. Pseudotumor cerebri following treatment with growth hormone [abstract]. Horm Res 1992: 37 Suppl.: 16
116. VanDop C, Conte FA, Koch TC, et al. Pseucotumor cerebri associated with initiation of levothyroxine therapy for juvenile hypothyroidism. N Engl J Med 1983; 30H: 1076-80
117. Hymes LC, Warsaw BL, Schwartz JF. Pseudotumor cerehri and thyroid replacement therapy [letter]. N Engl J Med 1983; 309: 732
118. Campos S, Olitsky S. Idiopathic intracranial hypertension after L-thyroxine therapy for acquired hypothyroidism. Clin Pediatr 1995; 34: 334-7
119. Raghavan S, DiMartino-Nardi J, Saenger P, et al. Pseudotumor cercbri in an infant after L-thyroxine therapy for transient neonatal hypothyroidism. J Pediatr 1997; 130: 478-80
120. Lessell S, Pediatric pseudotumor cerebri (idiopathic intracranial hypertension). Surv Ophthalmol 1993; 37: 155-66
121. Rappaporl EB, File D, Slipped capital femoral epiphysis in growth hormone deficient patients. Am J Dis Child 1985; 135: 396-9
122. Moshang T, Jr. Is brain tumor recurrence increased following growth hormone treatment? Trends Endocrinol Metab 1995; 10: 205-9
123. Ogilvy-Stuart AL. Safety of growth hormone after treatment of childhood malignancy. Horm Res 1995; 44 Suppl. 3:73-9
124. Cohn L, Feller AG, Draper MW, et al. Carpal tunnel syndrome and gynecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentration. Clin Endicrinol 1993; 39: 417-25
125. Holmes SJ, Shalet SM. Which adults develop side-effects of growth hormone replacement? Clin Endncrinol 1995; 43: 143-9
126. Grunfeld C, Sherman BM, Cavalieri RR. The acute effects of human growth hormone administration on thyroid function in normal men. J Clin Endocrinol Metab 1988; 67: 1111-4
127. 450-mediated antipyrine clearance in man. J Clin Endocrinol Metab 1996; 81: 1999-2000
128. I28. Pirazzoli R, Cacciari E, Mandini M, et al. Follow-up of antibodies to growth hormone in 210 growth hormone-deficient children treated with different commercial preparations. Acta Paediatr 1995; 84: 1233-6